ARS Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing neffy, for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, administered and nasal spray. Type I allergic reactions are potentially life-threatening hypersensitivity reactions that can occur within minutes of exposure to an allergen and need to be treated immediately to relieve symptoms and prevent further progression.
Símbolo de cotizaciónSPRY
Nombre de la empresaARS Pharmaceuticals Inc
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoMr. Richard E. Lowenthal
Número de empleados155
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 04
Dirección11682 El Camino Real, Suite 120
CiudadSAN DIEGO
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal92130
Teléfono18587719307
Sitio Webhttps://ars-pharma.com/
Símbolo de cotizaciónSPRY
Fecha de salida a bolsaDec 04, 2020
Director ejecutivoMr. Richard E. Lowenthal
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.

Sin datos